DK2931877T3 - Fremgangsmåder, som modulerer stamcellers immunregulerende virkning - Google Patents

Fremgangsmåder, som modulerer stamcellers immunregulerende virkning Download PDF

Info

Publication number: DK2931877T3
Authority: DK; Denmark
Prior art keywords: modulating; procedures; regulatory effect; immune regulatory; stam
Prior art date: 2012-12-14

Application number

DK13862510T

Other languages

English (en)

Inventor

Yufang Shi

Guangwen Ren

Liying Zhang

Original Assignee

Univ Rutgers

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-14

Filing date

2013-12-14

Publication date

2019-11-04

2013-12-14 Application filed by Univ Rutgers filed Critical Univ Rutgers

2019-11-04 Application granted granted Critical

2019-11-04 Publication of DK2931877T3 publication Critical patent/DK2931877T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2317—Interleukin-17 (IL-17)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Developmental Biology & Embryology (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Microbiology (AREA)
Virology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Diabetes (AREA)
Transplantation (AREA)
Pulmonology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK13862510T 2012-12-14 2013-12-14 Fremgangsmåder, som modulerer stamcellers immunregulerende virkning DK2931877T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261737616P	2012-12-14	2012-12-14
PCT/US2013/075208 WO2014093948A1 (en)	2012-12-14	2013-12-14	Methods modulating immunoregulatory effect of stem cells

Publications (1)

Publication Number	Publication Date
DK2931877T3 true DK2931877T3 (da)	2019-11-04

Family

ID=50935021

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK13862510T DK2931877T3 (da)	2012-12-14	2013-12-14	Fremgangsmåder, som modulerer stamcellers immunregulerende virkning

Country Status (9)

Country	Link
EP (2)	EP2931877B1 (da)
JP (5)	JP6377632B2 (da)
KR (2)	KR102188605B1 (da)
CN (2)	CN109576217A (da)
AU (2)	AU2013358904B2 (da)
CA (1)	CA2895148C (da)
DK (1)	DK2931877T3 (da)
ES (1)	ES2756336T3 (da)
WO (1)	WO2014093948A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI812867B (zh)	2011-11-30	2023-08-21	安斯泰來再生醫藥協會	利用血管母細胞產生間葉基質細胞之方法
US8961956B2 (en)	2011-11-30	2015-02-24	Ocata Therapeutics, Inc.	Mesenchymal stromal cells and uses related thereto
CA2876499C (en)	2012-07-12	2021-10-26	Imstem Biotechnology, Inc.	Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
WO2015172659A1 (zh) *	2014-05-14	2015-11-19	中国科学院上海生命科学研究院	Il-17在提高间充质干细胞免疫抑制功能中的应用
JP6898706B2 (ja) *	2015-01-05	2021-07-07	ナショナルヤン−ミンユニバーシティ	肝疾患を治療するための間葉系幹細胞
CN105838671A (zh) *	2015-01-16	2016-08-10	中国科学院上海生命科学研究院	I型干扰素及间充质干细胞在制备抗肿瘤药物中的新用途
CA2975147C (en) *	2015-01-31	2025-06-10	The Trustees Of The University Of Pennsylvania	COMPOSITIONS AND METHODS OF ADMINISTRATION OF THERAPEUTIC MOLECULES TO T CELLS
CA3037333A1 (en) *	2016-09-19	2018-03-22	University Of South Florida	Method of targeting oncolytic viruses to tumors
KR101971323B1 (ko) *	2016-10-17	2019-04-23	사회복지법인 삼성생명공익재단	면역질환 치료를 위한 고효능 줄기세포 선별방법
CA3042031A1 (en) *	2016-10-27	2018-05-03	The Trustees Of Columbia University In The City Of New York	Immunosuppressive mesenchymal cells and methods for forming same
KR102590455B1 (ko) *	2016-12-12	2023-10-17	베이징 헬스 앤드 바이오테크 스템 셀 테크놀로지칼 코포레이션 리미티드	주산기 조직 유래된 중간엽 줄기 세포: 그의 제조 방법 및 용도
EP3560527B1 (en) *	2016-12-16	2024-01-31	Regene Pharm Co., Ltd.	Tissue healing agent
CN107916253A (zh) *	2017-11-01	2018-04-17	上海隆耀生物科技有限公司	一种表达人源免疫刺激因子light的间充质干细胞的制备方法及制得的msc‑l细胞
EP3707515A1 (en) *	2017-11-06	2020-09-16	Kings College London	Therapeutic substances, their preparation and diagnostic procedure
CA3082368A1 (en) *	2017-11-09	2019-05-16	Sapporo Medical University	Medicine for tissue regeneration, and preparation method therefor
KR102096150B1 (ko) *	2018-01-05	2020-04-02	재단법인 아산사회복지재단	인터페론 감마로 전처리된 유도만능 줄기세포 유래 중간엽 줄기세포 및 이로부터 유래된 엑소좀을 포함하는 피부질환의 개선, 예방 또는 치료용 조성물
JP7273421B2 (ja)	2018-02-21	2023-05-15	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
CN108546674B (zh) *	2018-04-28	2021-10-19	暨南大学	预刺激干细胞及其制备方法和应用
KR102074798B1 (ko) *	2018-06-15	2020-02-07	코아스템(주)	자가면역질환 치료에 대한 유효성 예측용 바이오마커, 진단키트 및 치료용 용도
KR20210070349A (ko) *	2018-10-05	2021-06-14	보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템	중간엽 기질 세포의 증식 방법
CN109706180A (zh) *	2019-01-11	2019-05-03	杭州荣泽生物科技有限公司	一种脐带间充质干细胞过表达ido增强免疫抑制的方法及应用
AU2020228979B2 (en) *	2019-02-27	2025-05-29	Takeda Pharmaceutical Company Limited	Improved stem cell populations for allogeneic therapy
WO2021007180A1 (en) *	2019-07-05	2021-01-14	Case Western Reserve University	Priming media and methods for stem cell culture and therapy
CN114853869B (zh) *	2019-12-10	2023-12-26	湖南赛奥维生物技术有限公司	一种碱性成纤维细胞生长因子替代物及其组合物和应用
KR102268242B1 (ko) *	2020-01-06	2021-06-23	에스씨엠생명과학 주식회사	줄기세포의 기능강화용 조성물
WO2021162554A1 (en) *	2020-02-14	2021-08-19	Academisch Ziekenhuis Leiden H.O.D.N. Lumc	Means and methods for determining mesenchymal stromal cell properties.
CN111351942B (zh) *	2020-02-25	2024-03-26	北京尚医康华健康管理有限公司	肺癌肿瘤标志物筛选系统及肺癌风险分析系统
CN111206018A (zh) *	2020-02-25	2020-05-29	无锡市人民医院	一种用于治疗急性肝衰竭的间充质干细胞的制备方法
CN115605754A (zh) *	2020-04-20	2023-01-13	美商生命科学有限公司（Us）	效价测定
CN112111449A (zh) *	2020-09-03	2020-12-22	高连如	一种免疫调节功能预授权型间充质干细胞、制备方法及注射液
KR102492888B1 (ko) *	2020-12-23	2023-01-30	에스씨엠생명과학 주식회사	줄기세포 프라이밍 조성물 및 프라이밍된 줄기세포
CN113151164B (zh) *	2021-05-08	2023-08-18	中山大学	一种msc的培养基添加剂及其应用
CA3220002A1 (en) *	2021-05-13	2022-11-17	Primegen Us, Inc.	Methods and compositions for treating liver disease
KR102717862B1 (ko) *	2021-05-18	2024-10-15	에스씨엠생명과학 주식회사	기능강화 줄기세포를 포함하는 아토피 피부염 예방 또는 치료용 조성물
KR20220162394A (ko) *	2021-06-01	2022-12-08	에스씨엠생명과학 주식회사	기능강화 줄기세포 및 조절 t 세포를 포함하는 아토피 피부염 예방 또는 치료용 병용투여 조성물
CN114621919B (zh) *	2022-05-17	2022-12-06	天九再生医学(天津)科技有限公司	一种增强间充质干细胞免疫调节能力的方法
KR20230172252A (ko) *	2022-06-15	2023-12-22	에스씨엠생명과학 주식회사	기능강화 줄기세포를 포함하는 관절염 예방 또는 치료용 조성물
CN115161276B (zh) *	2022-08-24	2023-09-15	深圳市北科生物科技有限公司	Il4、il21、il27至少两种细胞因子处理获得的间充质干细胞及其外泌体和应用
CN115354022A (zh) *	2022-08-24	2022-11-18	深圳市北科生物科技有限公司	Il4、il21、il27至少两种细胞因子处理获得的间充质干细胞及其外泌体和应用
KR102522295B1 (ko) *	2022-08-30	2023-04-18	주식회사 스마트셀랩	말초혈액유래 줄기세포의 분리 및 배양조건과 이를 활용한 전구세포로의 분화유도
WO2024228384A1 (ja) *	2023-04-30	2024-11-07	国立大学法人北海道大学	免疫寛容誘導用組成物
CN118320101B (zh) *	2024-06-14	2024-09-17	天津嘉氏堂科技有限公司	iNOS抑制剂在制备治疗硬皮病胶原沉积药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10336152B4 (de)	2003-08-06	2007-02-15	Nephrogen LLC, Salt Lake City	Aufreinigungsverfahren für humane mesenchymale Stammzellen
KR20070100870A (ko)	2005-01-31	2007-10-12	가부시키가이샤 니콘	레이저 광원의 제어 방법, 레이저 광원 장치 및 노광 장치
US20070128722A1 (en)	2005-12-05	2007-06-07	Industrial Technology Research Institute	Human mesenchymal stem cells and culturing methods thereof
US8685728B2 (en) *	2008-01-31	2014-04-01	Rutgers The State University Of New Jersey	Kit containing stem cells and cytokines for use in attenuating immune responses

2013
- 2013-12-14 KR KR1020157018893A patent/KR102188605B1/ko active Active
- 2013-12-14 AU AU2013358904A patent/AU2013358904B2/en active Active
- 2013-12-14 DK DK13862510T patent/DK2931877T3/da active
- 2013-12-14 WO PCT/US2013/075208 patent/WO2014093948A1/en not_active Ceased
- 2013-12-14 JP JP2015548026A patent/JP6377632B2/ja active Active
- 2013-12-14 CA CA2895148A patent/CA2895148C/en active Active
- 2013-12-14 EP EP13862510.8A patent/EP2931877B1/en active Active
- 2013-12-14 KR KR1020207034754A patent/KR102353601B1/ko active Active
- 2013-12-14 EP EP19188908.8A patent/EP3587562B1/en active Active
- 2013-12-14 CN CN201811227664.6A patent/CN109576217A/zh active Pending
- 2013-12-14 ES ES13862510T patent/ES2756336T3/es active Active
- 2013-12-14 CN CN201380072996.0A patent/CN105008521B/zh active Active
2018
- 2018-07-25 JP JP2018139545A patent/JP6654670B2/ja active Active
2020
- 2020-01-30 JP JP2020013222A patent/JP6920644B2/ja active Active
- 2020-03-13 AU AU2020201856A patent/AU2020201856B2/en active Active
2021
- 2021-07-08 JP JP2021113276A patent/JP2021169478A/ja active Pending
2023
- 2023-04-13 JP JP2023065806A patent/JP7495695B2/ja active Active

Also Published As

Publication number	Publication date
KR20150118100A (ko)	2015-10-21
WO2014093948A1 (en)	2014-06-19
JP2020075935A (ja)	2020-05-21
AU2013358904A1 (en)	2015-07-09
JP6920644B2 (ja)	2021-08-18
CN109576217A (zh)	2019-04-05
EP2931877A4 (en)	2016-05-04
EP3587562A1 (en)	2020-01-01
EP2931877A1 (en)	2015-10-21
EP3587562B1 (en)	2021-03-24
AU2020201856A1 (en)	2020-04-02
CN105008521B (zh)	2018-11-20
KR102353601B1 (ko)	2022-01-19
CA2895148A1 (en)	2014-06-19
KR20200138833A (ko)	2020-12-10
AU2020201856B2 (en)	2022-07-14
ES2756336T3 (es)	2020-04-27
EP2931877B1 (en)	2019-07-31
KR102188605B1 (ko)	2020-12-08
CN105008521A (zh)	2015-10-28
JP2018184449A (ja)	2018-11-22
JP7495695B2 (ja)	2024-06-05
JP2021169478A (ja)	2021-10-28
JP2016504324A (ja)	2016-02-12
JP6654670B2 (ja)	2020-02-26
AU2013358904B2 (en)	2020-01-02
JP2023093589A (ja)	2023-07-04
HK1217211A1 (zh)	2016-12-30
JP6377632B2 (ja)	2018-08-22
CA2895148C (en)	2023-02-28

Publication	Publication Date	Title
DK2931877T3 (da)	2019-11-04	Fremgangsmåder, som modulerer stamcellers immunregulerende virkning
DK3363790T3 (da)	2020-04-27	1,2,4-oxadiazolderivater som immunmodulatorer
BR112014028602A2 (pt)	2017-06-27	formulação líquida.
FR2988154B1 (fr)	2016-02-19	Valve de distribution.
EP2813437A4 (en)	2015-10-21	BOTTLE
DK3263564T3 (da)	2020-09-07	Aza-aryl-1h-pyrazol-1-yl-benzen-sulfonamider som ccr(9)- antagonister
DK2867117T3 (da)	2020-02-17	Bæreplanssegl
EP2915757A4 (en)	2016-06-08	DOUBLE TANK
BR112015013892A2 (pt)	2017-07-11	simulador.
BR112014027026A2 (pt)	2017-06-27	aerofólio
EP2821349A4 (en)	2015-10-14	BOTTLE
EP2926685A4 (en)	2016-07-13	COSMETICS CONTAINER
CL2014003283A1 (es)	2016-04-01	Formulación farmacéutica.
LT2812013T (lt)	2019-07-10	Kompozicija, skirta džs gydymui
DK3003493T3 (da)	2020-01-13	Enzymatisk system, som indeholder kosmetiske sammensætninger
HRP20190229T1 (hr)	2019-04-05	Ormar, postupak za izradu ormara
FR2996109B1 (fr)	2016-01-01	Applicateur chauffant.
BR112015001416A2 (pt)	2017-07-04	plugue.
BR112014028443A2 (pt)	2017-06-27	composição estéril.
BR112014027645A2 (pt)	2018-04-10	5-halogenopirazol bifenilcarboxamidas.
DE112013002886A5 (de)	2015-02-19	Kosmetik-Behältnis
FR2990870B1 (fr)	2015-09-04	Autoinjecteur.
ES1077924Y (es)	2013-01-23	Marquesina seguidor solar
BR302012005829S1 (pt)	2014-05-27	Configuração aplicada pentenadeira.
FI10077U1 (fi)	2013-05-07	Tiivistejärjestely